Persistence and adherence with mirabegron versus antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice Prescription Database

被引：0
|
作者：
Wagg, Adrian [1 ]
Foley, Steve [2 ]
Peters, John [3 ]
Nazir, Jameel [4 ]
Kool-Houweling, Leanne [5 ]
Scrine, Ludmila [6 ]
机构：
[1] Univ Alberta, Med, Edmonton, AB, Canada
[2] Royal Berkshire Hosp, Dept Urol, Reading, Berks, England
[3] Barts Hlth NHS Trust, Whipps Cross Hosp, Dept Urol, London, England
[4] Astellas Pharma Europe Ltd, Hlth Econ & Outcomes Res, Chertsey, England
[5] Quintiles Advisory Serv, Hoofddorp, Netherlands
[6] Astellas Pharma Europe, Chertsey, England
来源：
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2017年 / 211卷
关键词：
D O I：
10.1016/j.ejogrb.2017.01.028
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
2
引用
收藏
页码：199 / 200
页数：2
相关论文
共 50 条
  • [31] Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care
    Mahmood Ali
    Sarah Grogan
    Sue Powell
    Leanne Staniford
    Jameel Nazir
    Margarita Landeira
    Patrick J. O. Covernton
    Ashley Jaggi
    Francis Fatoye
    Maxine Holt
    Advances in Therapy, 2019, 36 : 3110 - 3122
  • [32] Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care
    Ali, Mahmood
    Grogan, Sarah
    Powell, Sue
    Staniford, Leanne
    Nazir, Jameel
    Landeira, Margarita
    Covernton, Patrick J. O.
    Jaggi, Ashley
    Fatoye, Francis
    Holt, Maxine
    ADVANCES IN THERAPY, 2019, 36 (11) : 3110 - 3122
  • [33] A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments
    Bunniran, Suvapun
    Davis, Cralen
    Kristy, Rita
    Ng, Daniel
    Schermer, Carol R.
    Uribe, Claudia
    Suehs, Brandon T.
    NEUROUROLOGY AND URODYNAMICS, 2018, 37 (01) : 177 - 185
  • [34] Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome
    White, William B.
    Siddiqui, Emad
    Tat, Tri
    Franks, Billy
    Schermer, Carol R.
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2018, 12 (11) : 768 - 778
  • [35] Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice
    Shin, Jung Hyun
    Choo, Myung-Soo
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2019, 11 (03) : 151 - 157
  • [36] COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER
    Majd, Karimi Z.
    Taheri, S.
    Yousefi, N.
    Peiravian, F.
    VALUE IN HEALTH, 2019, 22 : S915 - S916
  • [37] Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice
    Yuan Chi Shen
    Hung Jen Wang
    Yao Chi Chuang
    International Urology and Nephrology, 2018, 50 : 1219 - 1226
  • [38] Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice
    Shen, Yuan Chi
    Wang, Hung Jen
    Chuang, Yao Chi
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (07) : 1219 - 1226
  • [39] Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis
    Schiavi, Michele C.
    Faiano, Pierangelo
    D'Oria, Ottavia
    Zullo, Marzio A.
    Muzii, Ludovico
    Panici, Pierluigi Benedetti
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (03) : 524 - 531
  • [40] Prescription Patterns in Asthma Patients Initiating Salmeterol in UK General Practice A Retrospective Cohort Study using the General Practice Research Database (GPRD)
    DiSantostefano, Rachael L.
    Davis, Kourtney J.
    DRUG SAFETY, 2011, 34 (06) : 511 - 520
12345